June 2007 Oncology News International

Publication
Article

Focus on Hematology

Meta-Analysis Shows Rituximab-Chemo Increases Overall Survival in Indolent/Mantle Cell Lymphoma

Velcade/Doxil Approved for Relapsed or Refractory Multiple Myeloma Pts

Focus on Breast Cancer

Novel PET Tracer Detects Breast Tumors and Mets

Vitamin E-Based Paclitaxel May Be Less Neurotoxic

Removing Stage IV Primary May Cut Mortality

Focus on Lung Cancer

Canfosfamide Boosts Chemotherapy's Benefit in NSCLC

Best Measure of Lung Cancer Screening: Curability or Mortality?

Industry Watch

Enrollment Begins for Phase I Trial of NPI-0052 in Myeloma

PEG-SN38 Shows Anti-Tumor Activity in Resistant Models

Cougar Biotechnology Reports Positive Data on CB7630

Focus on Colon Cancer

Colonoscopy With Polyp Removal Reduces Mortality

Surveillance Colonoscopy Guidelines Not Being Followed

Cancer Care & Economics

Virtual Colonoscopy Gaining New Respect as a Sensitive and Cost-Effective CRC Screening Tool

Medicare Reacts to Recent Scrutiny of ESAs

Value-Based Competition Key to Healthcare Reform

Focus on Oncology Nursing

Gastric Ca Registry IDs Those With CDH1 Mutation

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
Related Content